Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18173170 | INDOLE CARBOXAMIDE COMPOUNDS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17284250 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17693108 | METHODS FOR APPLYING TUMOR TREATING FIELDS IN COMBINATION WITH CANCER TREATING THERAPEUTICS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18256449 | BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders | Non-Final OA | Texas Tech University System |
| 18011637 | Combination Verapamil and Mometasone Therapy for the treatment of Chronic Rhinosinusitis | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 17266488 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 17789293 | Substituted Tricyclic Compounds | Non-Final OA | Lupin Limited |
| 18264973 | Administration of Resiniferatoxin For Treatment of Prostate Cancer | Non-Final OA | Sorrento Therapeutics, Inc. |
| 18253296 | USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR TREATING CANCERS | Non-Final OA | Bold Therapeutics Inc. |
| 18031701 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Non-Final OA | Ranok Therapeutics (Hangzhou) Co. Ltd. |
| 18030207 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS | Non-Final OA | EISAI R&D MANAGEMENT CO., LTD. |
| 17918911 | PHARMACEUTOCAL COMPOSITION CONTAINING N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY)PHENYL)-N?-(4FLUOROPHENLY)CYCLOPROPANE-1,1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE | Non-Final OA | MSN Laboratories Private Limited, R & D Center |
| 17641904 | METHODS OF TREATING CANCER | Final Rejection | Inspirna, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy